Evaluation of the Pharmacokinetics and Hepatoprotective Effects of Phillygenin in Mouse

Table 1

Effect of phillygenin/OFE on AST, ALT, SOD, and MDA activities in blood serum of normal and experimental mice (n = 6).

	ALT; (nmol/(s L))	AST; (nmol/(s L))	SOD; (U/mg protein)	MDA; (nmol/mg protein)
normal control	42.0 ± 7.26	183 ± 16.8	52.8 ± 4.90	1.75 ± 0.482
CCl4 control
positive control	70.0 ± 18.3^##	186 ± 10.4^##	47.2 ± 2.95^##	1.81 ± 0.270^##
150 mg/kg OFE	111 ± 43.1^##	175 ± 15.5^##	46.5 ± 4.25^#	1.82 ± 0.541^#
300 mg/kg OFE	109 ± 23.2^##	171 ± 30.4^##	45.9 ± 2.65^#	1.79 ± 0.250^##
600 mg/kg OFE	99.0 ± 25.7^##	178 ± 24.9^##	46.5 ± 3.63^#	1.76 ± 0.430^##
6 mg/kg phillygenin	111 ± 30.5^##	190 ± 29.2^##	46.4 ± 4.27^#	1.85 ± 0.820
12mg/kg phillygenin	112 ± 23.1^##	196 ± 28.4^##	46.9 ± 2.74^##	1.91 ± 0.224^##
24 mg/kg phillygenin	110 ± 16.4^##	192 ± 20.8^##	49.5 ± 6.89^#	1.92 ± 0.413^#

  p < 0.05,   p < 0.01 versus normal control group.
^#  p < 0.05, ^##  p < 0.01, versus CCl₄ control group.